{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:00:21Z","timestamp":1792594821253,"version":"4.5.0"},"reference-count":41,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.2217\/fon-2022-0975","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T11:59:58Z","timestamp":1676289598000},"page":"7-17","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1080","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2702-8225","authenticated-orcid":false,"given":"Barry","family":"Paul","sequence":"first","affiliation":[{"name":"Levine Cancer Institute,Department of Hematologic Oncology and Blood Disorders,\rCharlotte,\rNC 28204,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-5850","authenticated-orcid":false,"given":"Michaela","family":"Liedtke","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute,Stanford Comprehensive Cancer Center,\rStanford,\rCA94305,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"Taussig Cancer Institute,Cleveland Clinic,Department of Hematology and Medical Oncology,\rCleveland,\rOH 44195,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3141-1518","authenticated-orcid":false,"given":"Robert","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Rocky Mountain Cancer Centers,US Oncology Research,\rDenver,\rCO 80218,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3263-2374","authenticated-orcid":false,"given":"Mitul D","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Virginia Cancer Specialists,\rGainesville,\rVA 20155,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kin","sequence":"additional","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute,Wayne State University,Department of Oncology,\rDetroit,\rMI 48201,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe Y","family":"Levy","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center,Department of Hematology and Medical Oncology,\rDallas,\rTX 75246,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7571-1523","authenticated-orcid":false,"given":"Rebecca","family":"Silbermann","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University,Division of Hematology\/Medical Oncology,\rPortland,\rOR 97239,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8676-7840","authenticated-orcid":false,"given":"Francesca","family":"Cottini","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center,Department of Internal Medicine,\rColumbus,\rOH 43210,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W","family":"Sborov","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute,University of Utah,Department of Internal Medicine,\rSalt Lake City,\rUT 84112,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9407-6265","authenticated-orcid":false,"given":"Irwindeep","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Cross Cancer Institute,University of Alberta,Department of Oncology,\rEdmonton,\rAlberta,\rT6G 1Z2,\rCanada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyssa","family":"Villarreal","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,\rFoster City,\rCA 94404,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-6824","authenticated-orcid":false,"given":"Michael","family":"Murphy","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,\rFoster City,\rCA 94404,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4593-8572","authenticated-orcid":false,"given":"Lin","family":"Gu","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,\rFoster City,\rCA 94404,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Chen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,\rFoster City,\rCA 94404,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-0637","authenticated-orcid":false,"given":"Nishanthan","family":"Rajakumaraswamy","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc,\rFoster City,\rCA 94404,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5484-8731","authenticated-orcid":false,"given":"Saad Z","family":"Usmani","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center,\rNew York City,\rNY 10065,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25791"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903455"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2020.1800451"},{"key":"e_1_3_6_7_1","unstructured":"American Cancer Society . Drug therapy for multiple myeloma (2021). www.cancer.org\/cancer\/multiple-myeloma\/treating\/chemotherapy.html"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1813"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.015495"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13191"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0137345"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001375"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0037-T"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3931"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02397-7"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.2005344"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3171"},{"issue":"16","key":"e_1_3_6_21_1","article-title":"Tolerability and efficacy of the first-in-class anti-C47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results","volume":"40","author":"Daver NG","year":"2022","unstructured":"Daver NG , VyasP, KambhampatiSet al. Tolerability and efficacy of the first-in-class anti-C47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia: phase 1b results. J. Clin. Oncol.40(Suppl. 16), Abstract 7020 (2022).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.7017"},{"key":"e_1_3_6_23_1","unstructured":"ClinicalTrials.gov . Study of magrolimab in participants with solid tumors (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04827576"},{"key":"e_1_3_6_24_1","volume-title":"Prescribing information.","author":"Darzalex Faspro (daratumumab and hyaluronidase-fihj)","year":"2022","unstructured":"Darzalex Faspro (daratumumab and hyaluronidase-fihj) . Prescribing information.Janssen Biotech, Inc. 1-16 Horsham, PA, USA (2022)."},{"key":"e_1_3_6_25_1","volume-title":"Prescribing information.","author":"Darzalex (daratumumab)","year":"2022","unstructured":"Darzalex (daratumumab) . Prescribing information.Janssen Biotech, Inc. 1-16Horsham, PA, USA (2022)."},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2140-1"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3418"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315"},{"key":"e_1_3_6_30_1","volume-title":"Prescribing information.","author":"Pomalyst (pomalidomide)","year":"2021","unstructured":"Pomalyst (pomalidomide) . Prescribing information.Celgene Corporation. 1-16Summit, NJ, USA (2021)."},{"key":"e_1_3_6_31_1","volume-title":"Prescribing information.","author":"Revlimid (lenalidomide)","year":"2022","unstructured":"Revlimid (lenalidomide) . Prescribing information.Celgene Corporation.1-28Princeton, NJ, USA (2022)."},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4525"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.9.2943"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1781"},{"key":"e_1_3_6_35_1","volume-title":"Prescribing information.","author":"Kyprolis (carfilzomib)","year":"2022","unstructured":"Kyprolis (carfilzomib) . Prescribing information.Onyx Pharmaceuticals; Amgen Inc. 1-85Thousand Oaks, CA, USA (2022)."},{"key":"e_1_3_6_36_1","volume-title":"Prescribing information","author":"Velcade (bortezomib).","year":"2021","unstructured":"Velcade (bortezomib). Prescribing information.Takeda Pharmaceuticals America Inc. 1-44Lexington, MA, USA (2021)."},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-065888"},{"key":"e_1_3_6_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2867-5-18"},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126298"},{"key":"e_1_3_6_40_1","volume-title":"AACR Annual Meeting 2017.","author":"Linderoth E","year":"2017","unstructured":"Linderoth E , HelkeS, LeeVet al. The anti-myeloma activity of TTI-621 (SIRP\u03b1Fc), a CD47-blocking immunotherapeutic, is enhanced when combined with a proteasome inhibitor. Presented at: AACR Annual Meeting 2017.Washington, DC, USA (1\u20135 April 2017)."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101221"},{"key":"e_1_3_6_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"e_1_3_6_43_1","unstructured":"ClinicalTrials.gov . Study of magrolimab combinations in participants with relapsed\/refractory multiple myeloma (2022). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04892446"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2022-0975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T19:11:21Z","timestamp":1724353881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2022-0975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["10.2217\/fon-2022-0975"],"URL":"https:\/\/doi.org\/10.2217\/fon-2022-0975","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}